SCHEMBL7126711

SCHEMBL7126711

CC(=O)Nc1ccc(Oc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.47
PRKAA2 P54646 2/20 0.43
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 1/20 0.40
RAB9A P51151 4/20 0.40
MAPT P10636 3/20 0.40
MAPK1 P28482 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GFER P55789 1/20 0.40
PKM P14618 1/20 0.40
GALR3 O60755 1/20 0.40
HTT P42858 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SCN9A Q15858 1/20 0.39
KCNQ3 O43525 1/20 0.39
KCNQ2 O43526 1/20 0.39
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7119283 0.88 POLB (0.46) HRH3PRKAA2POLBSMN1; SMN2SCN9A
SCHEMBL7124977 0.88 MMP2 (0.41) SMN1; SMN2KMT2AMAPTALDH1A1HTT
SCHEMBL7122583 0.86 POLB (0.50) HRH3POLBSMN1; SMN2RAB9ASCN9A
SCHEMBL7123339 0.86 POLB (0.43) HRH3POLBSMN1; SMN2MAPTHTT
SCHEMBL7125166 0.86 KMT2A (0.40) HRH3PRKAA2SMN1; SMN2KMT2AHTT
SCHEMBL7124006 0.85 MAPT (0.40) HRH3RAB9AMAPTKCNQ3KCNQ2
SCHEMBL7125155 0.84 POLB (0.41) HRH3POLBSMN1; SMN2KMT2ARAB9A
SCHEMBL7123375 0.83 MEN1 (0.40) KMT2ARAB9ANPC1
SCHEMBL7117106 0.83 SCN9A (0.56) SCN9A
SCHEMBL7116059 0.82 POLB (0.39) POLBSMN1; SMN2KMT2ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 HRH3 2770/4885PRKAA2 1229/4885POLB 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.